logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

mCRC: new estimate of survival benefit of FOLFOXIRI

A first estimate of survival benefit, improved toxicity estimates for FOLFOXIRI plus bevacizumab.